Results 11 to 20 of about 681,456 (227)

Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases

Pharmaceutics, 2023
Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of rituximab.
Natalia Riva, Lucas Brstilo, Aymara Sancho-Araiz, Manuel Molina, Andrea Savransky, Georgina Roffé, Marianela Sanz, Silvia Tenembaum, Maria M. Katsicas, Iñaki F. Trocóniz, Paula Schaiquevich   +10 more
doaj   +1 more source

Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models [PDF]

Acta Cirúrgica Brasileira, 2018
Purpose: To evaluate the toxicity of Erbitux as well as its biosimilar APZ001 antibody (APZ001) in pre-clinical animal models including mice, rabbits and cynomolgus monkeys.
Xiaofei Wang, Jianmin Guo, Xinyu Deng, Yuankeng Huang, Caiguo Ye, Huiqing Liang, Junhua Rao, Wei Yang   +7 more
doaj   +2 more sources

Japanese regulation of biosimilar products: past experience and current challenges

British Journal of Clinical Pharmacology, 2016
Teruyo Arato
exaly   +2 more sources

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

Pharmaceuticals, 2021
Biosimilar medicines support the sustainability of national healthcare systems, by reducing costs of biological therapies through increased competition.
Y. Vandenplas, S. Simoens, P. Van Wilder, A. Vulto, I. Huys   +4 more
semanticscholar   +1 more source

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence

Ophthalmology and Therapy, 2022
To analyze the efficacy and safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab® (Intas Pharmaceuticals, Ahmedabad, India; BRm; Razumab®) and the innovator ranibizumab drug (IRm; LUCENTIS®) in Indian patients with polypoidal ...
Manoj Soman, Indu J. Nair, J. Sheth, Unnikrishnan Nair   +3 more
semanticscholar   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Pharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
M. García-Goñi, Isabel Río‐Álvarez, D. Carcedo, A. Villacampa   +3 more
semanticscholar   +1 more source

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases

Ophthalmology and Therapy, 2021
To assess the safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab® (Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real-world conditions. This was a multicenter, retrospective chart review which included
D. Chakraborty, M. Stewart, J. Sheth, T. Sinha, S. Boral, Arnab Das, S. Mondal, Angshuman Mukherjee   +7 more
semanticscholar   +1 more source

Portuguese Position Paper on the Use of Biosimilars in Psoriasis

Acta Médica Portuguesa, 2016
Keywords: Biological Agents; Biosimilar Pharmaceuticals; Portugal; Psoriasis/drug therapy.
Tiago Torres, Ana Ferreira, Paulo Ferreira, Martinha Henriques, Luiz Leite, Sofia Magina, Gabriela Marques Pinto, Hugo Oliveira, Artur Sousa Basto, Rui Tavares Bello, Paulo Varela, Antonio Massa, Manuela Selores, Paulo Filipe, On behalf of The Portuguese College of Dermatology, On behalf of The Portuguese Society of Dermatology and Venereology   +15 more
doaj   +1 more source

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis

Systematic Reviews, 2021
Background Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide.
Bruna O. Ascef, Matheus O. Almeida, Ana Cristina de Medeiros Ribeiro, Danieli C. O. Andrade, Haliton A. de Oliveira Júnior, Tiago V. Pereira, Patrícia C. de Soárez   +6 more
doaj   +1 more source

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? [PDF]

The European Journal of Health Economics, 2013
Biological medicines contain a biological substance that is produced by or derived from a living organism. The active substances of biologicals are usually larger and more complex than those of chemically derived medicines (non-biological medicine). Biologicals are used for the treatment of chronic and life-threatening diseases such as cancer, multiple
Farfan-Portet, María-Isabel, Gerkens, Sophie, Lepage-Nefkens, Isabelle, Vinck, Irmgard, Hulstaert, Frank   +4 more
openaire   +2 more sources